AUTLAutolus Therapeutics plc
$1.77+18% 1Y
$1.77
$1.2152 weeks$2.54
AUTL in its own filings
AUTL's filing record carries 2 kinds of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
172
Events found in the filings · across 336 filings · the record starts in 2018
- Hard flags
- 2
Hard flags
- Most recent filing
- Aug 11, 2026
Most recent filing · Form 10-Q
- Record starts
- Mar 9, 2018
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 11, 2026
- Restatement admitted (non-reliance)past_3y
- 2024-03-21
- Change in certifying accountantpast_year
- 2026-04-16
- Late periodic reportpast_3y
- 2024-05-13
- SEC comment-letter activity34 occurrences
- 2026-05-01
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 11, 20261 Gross margin percentage represents gross margin (net product revenue less cost of sales) divided by net product revenue.Earnings release · press release
- Aug 3, 2026On August 3, 2026, the Company announced an increase in full year 2026 guidance for AUCATZYL® net product revenue to $140 million to $150 million, from between $120 million to $135 million.Regulation FD disclosure · Form 8-K
- Aug 3, 2026Perceptive Senior Secured Notes Facility On July 30, 2026 (the “Closing Date”), Autolus Therapeutics plc (the “Company”) entered into a Note Purchase Agreement and Guaranty (the “Note Purchase Agreement”) with certain subsidiaries of the Company, as guarantors, the noteholders party thereto and Perceptive Credit …Material agreement entered · Form 8-K
- Jun 9, 2026On June 5, 2026, Autolus Therapeutics plc (the “Company”) published its UK Annual Report and Accounts for the year ended December 31, 2025 (the “UK Annual Report”) and distributed a notice of its annual general meeting to be held on June 29, 2026 (the “AGM”), a form of proxy and its UK Annual Report to its ordinary …Other event · Form 8-K
- May 14, 2026Amanda Cray +1 617-967-0207 a.cray@autolus.com.Earnings release · press release
- Apr 29, 2026On April 29, 2026, Autolus Therapeutics plc (the “Company”) announced its Board of Directors approved a plan to improve operational efficiency and reduce operating expenses.Exit or disposal costs (restructuring) · Form 8-K
- Apr 16, 2026On April 14, 2026, the Audit Committee of the Board of Directors (the “Audit Committee”) of Autolus Therapeutics plc (the “Company”) dismissed Ernst & Young LLP (UK) (“EY UK”) as the Company’s independent registered public accounting firm.Auditor change · Form 8-K
- Apr 8, 2026Spotlight on the Acute Lymphoblastic Leukemia (ALL) Business AUTOLUS INVESTOR EVENT April 8, 2026 EX-99.1.Regulation FD disclosure · press release
- Jan 26, 2026On January 21, 2026, Autolus Limited, a wholly owned subsidiary of Autolus Therapeutics plc (the “registrant”, and together with Autolus Limited, the “Company”), entered into a Master Service Agreement with AGC Biologics S.p.A (“AGC”) for the manufacture and supply of lentiviral vector (the “Agreement”), a raw …Material agreement entered · Form 8-K
- Jan 12, 2026On January 12, 2026, the Company announced preliminary unaudited AUCATZYL net product revenue of approximately $24 million for the fourth quarter of 2025 and approximately $75 million for the full year of 2025.Regulation FD disclosure · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…